Observation on the Therapeutic Maintaining Time of 58 Thalassemia Cases after Medication of Reinforcing Kidney and Replenishing Marrow

WANG Wen-Juan1; WU Zhi-Kui1; ZHANG Xin-Hua2; et al.

doi:10.13288/j.11-2166/r.2008.07.011

您当前的位置：

首页 >

文章列表页 >

Observation on the Therapeutic Maintaining Time of 58 Thalassemia Cases after Medication of Reinforcing Kidney and Replenishing Marrow

更新时间：2021-11-17

- Observation on the Therapeutic Maintaining Time of 58 Thalassemia Cases after Medication of Reinforcing Kidney and Replenishing Marrow
- Journal of Traditional Chinese Medicine Issue 7, Pages: 608-610(2008)
- 作者机构：
  
  1. 首都医科大学中医药学院中医系
  2. 中国中医科学院广安门医院分子生物学研究室
  3. 中国人民解放军第三○三医院血液科
  4. 中国人民解放军第三○三医院血液科北京市右安门外西头条10号
  5. ,100069
- 作者简介：
- 基金信息：
- DOI：10.13288/j.11-2166/r.2008.07.011
  CLC： R259
- Published：2008
- 稿件说明：
移动端阅览
[1]王文娟,吴志奎,张新华,王荣新,刘咏梅,方素萍,张冲,周天红,李平萍,罗瑞贵.补肾益髓法治疗地中海贫血患者58例停药后疗效维持时间观察[J].中医杂志,2008(07):608-610.

WANG Wen-Juan1, WU Zhi-Kui1, ZHANG Xin-Hua2, et al. Observation on the Therapeutic Maintaining Time of 58 Thalassemia Cases after Medication of Reinforcing Kidney and Replenishing Marrow[J]. Journal of Traditional Chinese Medicine2008, (7): 608-610.
[1]王文娟,吴志奎,张新华,王荣新,刘咏梅,方素萍,张冲,周天红,李平萍,罗瑞贵.补肾益髓法治疗地中海贫血患者58例停药后疗效维持时间观察[J].中医杂志,2008(07):608-610. DOI： 10.13288/j.11-2166/r.2008.07.011.

WANG Wen-Juan1, WU Zhi-Kui1, ZHANG Xin-Hua2, et al. Observation on the Therapeutic Maintaining Time of 58 Thalassemia Cases after Medication of Reinforcing Kidney and Replenishing Marrow[J]. Journal of Traditional Chinese Medicine2008, (7): 608-610. DOI： 10.13288/j.11-2166/r.2008.07.011.

摘要

目的观察补肾益髓法治疗地中海贫血（以下简称"地贫"）的临床后效应。方法纳入58例地贫患者对其进行停药后疗效维持时间观察及不同相关因素对疗效维持时间的影响。结果58例患者停药后疗效维持时间一般为3～6个月

平均疗效维持时间约为4个月

并且疗效维持时间不受性别、临床分型、基因型以及地贫类型等相关因素的影响。结论补肾益髓法治疗地贫不仅能够在治疗期间产生较好的临床效果

在停药后仍能继续维持该疗效4个月左右

说明该法治疗地贫具有良好的临床后效应。

Abstract

Objective To observe the maintaining time of therapeutic effect of thalassemia after medication of reinforcing kidney and replenishing marrow.Methods Included were 58 cases of thalassemia

and the maintaining time of therapeutic effect after medication and the influence of relating factors on it were taken into the observation.Results The therapeutic effect was lasting for 3～6 months generally

on average 4 months

and not affected by sex

clinical phenotype

genotype and type of thalassemia.Conclusion The method of reinforcing kidney and replenishing marrow in the treatment of thalassemia is not only effective during the medication but also maintained effective for more or less 4 months

indicating that it has a post-medication effect for thalassemia patients.

关键词

Keywords

references

查看原文

Views

108

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Syndrome Differentiation and Treatment of Thalassemia based on the Theory of “Kidney Stores Essence and Produces Marrow”

Effect of Yisui Shengxue Granules on the Proliferation of Hematopoietic Progenitor Cells in Irradiated Mice

Relationship between Different Types and Genotypes of Thalassemia and Kidney Deficiency Syndrome

Clinical Research on Yisui Shengxue Granules in Treating Thalassemia with Kidney Deficiency Syndromes

A Prospective Study on Yisui Shengxue Granules for Thalassemia

Related Author

Yanling CHENG

Yuwen SUN

Lili HE

Zhikui WU

Kebo GU

GAO Yue

TAN Hongling

WU Zhikui

Related Institution

The Southern Campus of Guang'anmen Hospital， China Academy of Chinese Medical Sciences

Guang 'anmen Hospital，China Academy of Chinese Medical Sciences

Academy of Military Medical Sciences

Guang’ anmen Hospital,China Academy of Chinese Medical Sciences

Hospital of People’s Liberation Army

Address：No.16, Nanxiao street, Dongzhimen, Dongcheng District, Beijing Postal code：100700
Tel：010-64035632 Email：jtcmcn@188.com
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备09064830号-19 京公网安备11010102007558号
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰